非酒精性脂肪性肝病（NAFLD）已成为全球最常见的慢性肝病。尽管NAFLD与肥胖和2型糖尿病密切相关，但这种肝病也会影响非肥胖人群。NAFLD会增加患者心血管疾病、慢性肾脏疾病和某些肝外癌症的风险。尽管过去二十年间进行了众多临床试验，目前仍没有任何被授权用于NAFLD治疗的药物。当前，在试验环境中成功治疗NAFLD的药物非常有限，其原因尚未完全理解。由于心血管疾病是NAFLD患者死亡的主要原因，未来的NAFLD药物治疗必须考虑与心脏代谢风险因素相关的问题。在治疗患有NAFLD的2型糖尿病患者中，降糖药物的成功使用表明了这一策略的重要性，并值得进一步开发。由于合作是成功治疗的整体方法所必需的，因此需要提高公众对NAFLD的认识。版权所有 © 2023 Elsevier Ltd. 保留所有权利。

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver disease also affects individuals who do not have obesity. NAFLD increases the risk of developing cardiovascular disease, chronic kidney disease, and certain extrahepatic cancers. There is currently no licensed pharmacotherapy for NAFLD, despite numerous clinical trials in the past two decades. Currently, the reason so few drugs have been successful in the treatment of NAFLD in a trial setting is not fully understood. As cardiovascular disease is the predominant cause of mortality in people with NAFLD, future pharmacotherapies for NAFLD must consider associated cardiometabolic risk factors. The successful use of glucose-lowering drugs in the treatment of type 2 diabetes in patients with NAFLD indicates that this strategy is important, and worth developing further. Greater public awareness of NAFLD is needed because collaboration between all stakeholders is vital to enable a holistic approach to successful treatment.Copyright © 2023 Elsevier Ltd. All rights reserved.